RxDoctor Payments Data

Vincent Valdez, MD

Pain Medicine · Downey, CANPI 1588633762

Payments from drug & device makers

$8,936in general payments, 2019–2025

Across 405 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$2K
  • Vertiflex, Inc.$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$642
  • Abbott$233
  • Redhill Biopharma Inc.$216
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$7168%
  • Food & beverage$8,22192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,936 in reported general payments places this provider in the 75th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$463,230
Medicare patients
517
Services billed
3,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PercocetOxycodone Hcl/Acetaminophen12$46,571
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen255$36,515
Lidocaine68$11,800
MovantikNaloxegol Oxalate30$11,295
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen449$10,719
Diclofenac Sodium78$6,295
OxycontinOxycodone Hcl13$6,142
Oxycodone Hcl156$4,916
Gabapentin433$4,760
Morphine Sulfate ErMorphine Sulfate125$3,928
Pregabalin129$3,208
Cyclobenzaprine Hcl111$1,000
Duloxetine Hcl95$991
Methocarbamol62$659
Baclofen73$598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$216$11,29530 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 840 pain medicine providers in California.

Other pain medicine in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →